Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
Cyclic nucleotide phosphodiesterase 1C contributes to abdominal aortic aneurysm.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
Genetic Deletion and Pharmacological Inhibition of PDE10A Protects Mice from Diet-Induced Obesity and Insulin Resistance.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
Hypothalamic PDE3B deficiency alters body weight and glucose homeostasis in mouse
3',5'-cyclic-nucleotide phosphodiesterase deficiency
PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity.
3',5'-cyclic-nucleotide phosphodiesterase deficiency
Role of cAMP-Phosphodiesterase 1C Signaling in Regulating Growth Factor Receptor Stability, Vascular Smooth Muscle Cell Growth, Migration, and Neointimal Hyperplasia.
Abortion, Habitual
Phosphodiesterase 8B gene polymorphism in women with recurrent miscarriage: a retrospective case control study.
Acquired Immunodeficiency Syndrome
Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.
Acute Kidney Injury
Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP.
Acute Kidney Injury
The role of phosphodiesterase 3 in endotoxin-induced acute kidney injury.
Acute Lung Injury
Inhaled milrinone attenuates experimental acute lung injury.
Acute Lung Injury
Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.
Acute Lung Injury
Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia.
Acute Lung Injury
Short-term cardiovascular effects of selective phosphodiesterase 3 inhibitor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in a meconium-induced acute lung injury.
Adenocarcinoma
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Adenocarcinoma
HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism.
Adenocarcinoma
PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Adenocarcinoma
SFPQ, a multifunctional nuclear protein, regulates the transcription of PDE3A.
Adenocarcinoma of Lung
A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.
Adenocarcinoma of Lung
PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Adenoma
Abnormalities of cAMP signaling are present in adrenocortical lesions associated with corticotropin-independent Cushing syndrome despite the absence of mutations in known genes.
Adenoma
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
Adenoma
Alterations of Phosphodiesterases in Adrenocortical Tumors.
Adenoma
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.
Adenoma
Effect of adenosine 3',5'-cyclic monophosphate (cAMP) on human non-tumorigenic and tumorigenic parotid acinar cells in culture.
Adenoma
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
Adenoma
Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas.
Adenoma
Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.
Adenoma
Phosphodiesterases and cAMP Pathway in Pituitary Diseases.
Adenoma
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Adenomatous Polyposis Coli
Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors.
Adrenal Cortex Neoplasms
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Adrenal Insufficiency
Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.
Adrenocortical Adenoma
Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas.
Adrenocortical Adenoma
Multiple endocrine neoplasias: advances and challenges for the future.
Adrenocortical Adenoma
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Adrenocortical Carcinoma
Studies on adrenocortical carcinoma of rat cyclic nucleotide phosphodiesterase activities.
Adrenoleukodystrophy
Therapy for X-adrenoleukodystrophy: normalization of very long chain fatty acids and inhibition of induction of cytokines by cAMP.
Ageusia
Gustin from human parotid saliva is carbonic anhydrase VI.
Alzheimer Disease
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
Alzheimer Disease
Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.
Alzheimer Disease
Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease.
Alzheimer Disease
Cilostazol restores autophagy flux in bafilomycin A1-treated, cultured cortical astrocytes through lysosomal reacidification: roles of PKA, zinc and metallothionein 3.
Alzheimer Disease
Correction to: Zhang et al., Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.
Alzheimer Disease
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Alzheimer Disease
Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
Alzheimer Disease
Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer's Disease.
Alzheimer Disease
Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
Alzheimer Disease
Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.
Alzheimer Disease
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
Alzheimer Disease
Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease.
Alzheimer Disease
Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques.
Alzheimer Disease
Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.
Alzheimer Disease
Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
Alzheimer Disease
Identification and characterisation of the novel amyloid-beta peptide-induced protein p17.
Alzheimer Disease
Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations.
Alzheimer Disease
Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.
Alzheimer Disease
PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Alzheimer Disease
Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.
Alzheimer Disease
Phosphodiesterase 4D: an enzyme to remember.
Alzheimer Disease
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide.
Alzheimer Disease
RNA Interference-Mediated Knockdown of Long-Form Phosphodiesterase-4D (PDE4D) Enzyme Reverses Amyloid-?42-Induced Memory Deficits in Mice.
Alzheimer Disease
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Alzheimer Disease
Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.
Anaphylaxis
Mechanism of action of 6, 7, 8, 9, 10, 12-hexahydro-azepino-[2, 1-b] quinazolin-12-one-(RLX)--a novel bronchodilator.
Anemia
Fine Epitope Specificity of Anti-erythropoietin Antibodies Reveals Molecular Mimicry With HIV-1 p17 Protein: A Pathogenetic Mechanism for HIV-1-Related Anemia.
Anemia, Sickle Cell
High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Aneurysm
Cyclic nucleotide phosphodiesterase 1C contributes to abdominal aortic aneurysm.
Ankylosis
Central role of pyrophosphate in acellular cementum formation.
Aortic Aneurysm
Cyclic nucleotide phosphodiesterase 1C contributes to abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Cyclic nucleotide phosphodiesterase 1C contributes to abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Suppression of Experimental Abdominal Aortic Aneurysm in a Rat Model by the Phosphodiesterase 3 Inhibitor Cilostazol.
Aortic Valve Stenosis
Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.
Arrhythmias, Cardiac
Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts.
Arrhythmias, Cardiac
Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction.
Arrhythmias, Cardiac
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Arrhythmias, Cardiac
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arrhythmogenic Right Ventricular Dysplasia
Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice.
Arteritis
Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate.
Arthritis, Psoriatic
Apremilast: first global approval.
Arthritis, Rheumatoid
Apremilast: first global approval.
Arthritis, Rheumatoid
Diosgenin Inhibits Excessive Proliferation and Inflammatory Response of Synovial Fibroblasts in Rheumatoid Arthritis by Targeting PDE3B.
Asthma
3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.
Asthma
?2-Agonists upregulate PDE4 mRNA but not protein or activity in human airway smooth muscle cells from asthmatic and nonasthmatic volunteers.
Asthma
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Asthma
Analyses of shared genetic factors between asthma and obesity in children.
Asthma
Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia.
Asthma
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Asthma
cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.
Asthma
Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Asthma
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Asthma
Cyclic nucleotide phosphodiesterases and methyltransferases in purified lymphocytes, monocytes and polymorphonuclear leucocytes from healthy donors and asthmatic patients.
Asthma
Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.
Asthma
Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma.
Asthma
Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Asthma
Effects of milrinone, sulmazole and theophylline on adenosine enhancement of antigen-induced bronchoconstriction and mediator release in rat isolated lungs.
Asthma
Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene.
Asthma
Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease?
Asthma
HLA-DQ strikes again: genome-wide association study further confirms HLA-DQ in the diagnosis of asthma among adults.
Asthma
Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
Asthma
Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma.
Asthma
Molecular docking and network connections of active compounds from the classical herbal formula Ding Chuan Tang.
Asthma
Pathogenesis of allergic airway inflammation.
Asthma
PDE11A associations with asthma: results of a genome-wide association scan.
Asthma
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
Asthma
Phosphodiesterases inhibition by Bacilli Calmette-Guérin contributes to decrease asthma in allergic rats.
Asthma
Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
Asthma
Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma.
Asthma
Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Asthma
RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients.
Asthma
Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects.
Asthma
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Asthma
Treating COPD with PDE 4 inhibitors.
Asthma
[cAMP phosphodiesterase activity in the leukocytes in bronchial asthma]
Asthma
[Characteristics of the action of euphylline and the activity of forms of cAMP phosphodiesterase in lymphocytes of patients with bronchial asthma]
Asthma
[Cyclic nucleotides phosphodiesterase activity in a rat lung model of asthma]
Asthma
[Effect of euphylline on the cyclic nucleotide content and cAMP phosphodiesterase activity of the lymphocytes of bronchial asthma patients]
Astrocytoma
Identification of novel genetic alterations in samples of malignant glioma patients.
Astrocytoma
Molecular markers that identify human astrocytomas and oligodendrogliomas.
Astrocytoma
Sustained entry of Ca2+ is required to activate Ca2+-calmodulin-dependent phosphodiesterase 1A.
Ataxia
Breaks in coordination: DNA repair in inherited ataxia.
Atherosclerosis
Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice.
Atherosclerosis
Association of GWAS-susceptibility loci with ischemic stroke recurrence in a Han Chinese population.
Atherosclerosis
Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.
Atherosclerosis
Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages.
Atherosclerosis
circRNA/lncRNA-miRNA-mRNA Network in Oxidized, Low-Density, Lipoprotein-Induced Foam Cells.
Atherosclerosis
CircSCAP aggravates oxidized low-density lipoprotein-induced macrophage injury by upregulating PDE3B via miR-221-5p in atherosclerosis.
Atherosclerosis
Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation.
Atherosclerosis
Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats.
Atherosclerosis
Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study.
Atherosclerosis
Impact of cilostazol on the progression of carotid atherosclerosis in patients with retinal vascular occlusion.
Atherosclerosis
Integrin ?5?1 regulates PP2A complex assembly through PDE4D in atherosclerosis.
Atherosclerosis
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.
Atherosclerosis
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Atherosclerosis
Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke.
Atherosclerosis
Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival.
Atherosclerosis
Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
Atherosclerosis
Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis.
Atherosclerosis
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Atherosclerosis
Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
Atrial Fibrillation
Phosphodiesterase4D (PDE4D)--A risk factor for atrial fibrillation and stroke?
Atrial Fibrillation
Suppression of experimental atrial fibrillation in a canine model of rapid atrial pacing by the phosphodiesterase 3 inhibitor cilostazol.
Atrioventricular Block
Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block.
Autoimmune Diseases
Association of established hypothyroidism-associated genetic variants with Hashimoto's thyroiditis.
Autoimmune Diseases
microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance.
Autoimmune Diseases
Novel associations for hypothyroidism include known autoimmune risk loci.
Basal Ganglia Diseases
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
Basal Ganglia Diseases
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Basal Ganglia Diseases
Neurodegenerative disease: Changes in brain phosphodiesterase 10A levels in neurodegenerative basal ganglia disorders.
Bone Diseases, Developmental
Acrodysostosis syndromes.
Bone Diseases, Developmental
[Genes in the cAMP pathway causing skeletal dysplasia with or without hormonal resistance].
Bone Resorption
Comparative study of the effects of cyclic nucleotide phosphodiesterase inhibitors on bone resorption and cyclic AMP formation in vitro.
Bone Resorption
Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor.
Brachydactyly
A PDE3A mutation in familial hypertension and brachydactyly syndrome.
Brachydactyly
Different mutations in PDE4D associated with developmental disorders with mirror phenotypes.
Brachydactyly
Hypertension and brachydactyly syndrome associated with vertebral artery malformation caused by a PDE3A missense mutation.
Brachydactyly
Hypertension linked to PDE3A activation.
Brachydactyly
PDE3A gene screening improves diagnostics for patients with Bilginturan syndrome (hypertension and brachydactyly syndrome).
Brachydactyly
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Brachydactyly
PDE3A variant associated with hypertension and brachydactyly syndrome in a patient with ischemic stroke caused by spontaneous intracranial artery dissection: A review of the clinical and molecular genetic features.
Brachydactyly
Phosphodiesterase 3A and Arterial Hypertension.
Brachydactyly
Whole-exome sequencing identifies a de novo PDE3A variant causing autosomal dominant hypertension with brachydactyly type E syndrome: a case report.
Bradycardia
Efficacy of Cilostazol in Prevention of Bradycardia during Carotid Artery Stenting.
Bradycardia
Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway.
Bradycardia
Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro.
Brain Diseases
Calcium metabolism in aluminum encephalopathy.
Brain Diseases
Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder.
Brain Diseases
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide.
Brain Injuries
Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.
Brain Injuries
Granulocyte-colony stimulating factor activates JAK2/PI3K/PDE3B pathway to inhibit corticosterone synthesis in a neonatal hypoxic-ischemic brain injury rat model.
Brain Injuries, Traumatic
A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury.
Brain Injuries, Traumatic
Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.
Brain Ischemia
Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.
Brain Ischemia
Ischemia-Induced Increase in Microvascular Phosphodiesterase 4D Expression in Rat Hippocampus Associated with Blood Brain Barrier Permeability: Effect of Age.
Brain Ischemia
Neuroprotection of benzoinum in cerebral ischemia model rats via the ACE-AngI-VEGF pathway.
Brain Ischemia
Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Brain Ischemia
[A clinical and genetic analysis of risk factors for the development of acute and chronic cerebral ischemia].
Brain Neoplasms
Calmodulin-dependent cyclic nucleotide phosphodiesterase in human cerebral cortex and glioblastoma multiforme.
Brain Neoplasms
Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule.
Breast Neoplasms
3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Breast Neoplasms
Alternative mechanisms of action of anti-oestrogens.
Breast Neoplasms
An exome-wide analysis of low frequency and rare variants in relation to risk of breast cancer in African American Women: the AMBER Consortium.
Breast Neoplasms
H-prune-nm23-H1 protein complex and correlation to pathways in cancer metastasis.
Breast Neoplasms
Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer.
Breast Neoplasms
Inhibition of breast cancer cell migration by activation of cAMP signaling.
Breast Neoplasms
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.
Breast Neoplasms
Overexpression of h-prune in breast cancer is correlated with advanced disease status.
Breast Neoplasms
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Breast Neoplasms
Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility.
Breast Neoplasms
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis.
Breast Neoplasms
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Breast Neoplasms
The Role of PDE8 in T Cell Recruitment and Function in Inflammation.
Breast Neoplasms
Understanding h-prune biology in the fight against cancer.
Breast Neoplasms
Unraveling genes and pathways influenced by H-prune PDE overexpression: a model to study cellular motility.
Bronchial Spasm
Aminophylline reduces the depth and duration of sedation with barbiturates.
Bronchial Spasm
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
Brugada Syndrome
Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.
Burkitt Lymphoma
[Phosphatidylethanolamine methylase and cyclic nucleotide phosphodiesterase activities in human B lymphoid hemopathies]
Carcinogenesis
?-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.
Carcinogenesis
Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?
Carcinogenesis
Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines.
Carcinogenesis
Inhibition of TPL2 by interferon-? suppresses bladder cancer through activation of PDE4D.
Carcinogenesis
Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma.
Carcinogenesis
miR-139/PDE2A-Notch1 feedback circuit represses stemness of gliomas by inhibiting Wnt/?-catenin signaling.
Carcinogenesis
Molecular Genetic and Genomic Alterations in Cushing's Syndrome and Primary Aldosteronism.
Carcinogenesis
Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway.
Carcinogenesis
Pde8b haploinsufficiency in mice is associated with modest adrenal defects, impaired steroidogenesis, and male infertility, unaltered by concurrent PKA or Wnt activation.
Carcinogenesis
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and ?-catenin-dependent TCF transcriptional activity.
Carcinogenesis
Phosphodiesterases and cAMP Pathway in Pituitary Diseases.
Carcinogenesis
Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.
Carcinoma
3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Carcinoma
A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.
Carcinoma
Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma.
Carcinoma
Antiviral activity of lambda-, beta-, and gamma-interferons in the presence of theophylline: involvement of 2',5'-oligo(A) synthetase.
Carcinoma
Biochemical properties of cyclic nucleotide phosphodiesterase in metastasizing and nonmetastasizing rat mammary carcinomas.
Carcinoma
cAMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
Carcinoma
Characterisation of cyclic adenosine 3':5'-monophosphate phospodiesterase from Walker carcinoma sensitive and resistant to bifunctional alkylating agents.
Carcinoma
Cyclic adenosine monophosphate-phosphodiesterase (cAMP-PDE) in lymphocytes from patients with stage III and IV squamous cell carcinoma of the head and neck.
Carcinoma
Cyclic nucleotide phosphodiesterase activity in muscle of patients with carcinoma.
Carcinoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Carcinoma
Effect of adenosine 3',5'-cyclic monophosphate (cAMP) on human non-tumorigenic and tumorigenic parotid acinar cells in culture.
Carcinoma
Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells.
Carcinoma
Expression of PDE11A in normal and malignant human tissues.
Carcinoma
h-prune Is an Independent Prognostic Marker for Survival in Esophageal Squamous Cell Carcinoma.
Carcinoma
Immunocytochemical demonstration of calmodulin and its activated forms in normal and carcinomatous human mammary tissue.
Carcinoma
Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Carcinoma
miR-5701 promoted apoptosis of clear cell renal cell carcinoma cells by targeting phosphodiesterase-1B.
Carcinoma
PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Carcinoma
Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
Carcinoma
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Carcinoma
Targeting tumor cells based on Phosphodiesterase 3A expression.
Carcinoma
[Biochemical differences in the tumor cells of 5-fluorouracil-sensitive and -resistant strains of Ehrlich ascitic carcinoma]
Carcinoma
[Effect of human interferons on cAMP phosphodiesterase activity in a culture of human ovarian carcinoma cells (CaOv)]
Carcinoma, Brown-Pearce
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Carcinoma, Hepatocellular
Ca2+-independent cyclic GMP phosphodiesterases from rat liver and HTC hepatoma cells.
Carcinoma, Hepatocellular
Different effects of selenium on cyclic AMP metabolism in hepatoma cells and normal liver cells.
Carcinoma, Hepatocellular
Differential expression of cGMP-inhibited cyclic nucleotide phosphodiesterases in human hepatoma cell lines.
Carcinoma, Hepatocellular
Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins.
Carcinoma, Hepatocellular
Hepatocellular carcinoma: H-Prune gene regulatory networks.
Carcinoma, Hepatocellular
Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).
Carcinoma, Hepatocellular
Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Multisite phosphorylation of adipocyte and hepatocyte phosphodiesterase 3B.
Carcinoma, Hepatocellular
Regulation of cyclic nucleotide phosphodiesterases in cultured hepatoma cells by dexamethasone and N6,O2'-dibutyryl adenosine 3':k'-monophosphate.
Carcinoma, Hepatocellular
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Carcinoma, Hepatocellular
The antitumour agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) inhibits rat liver cAMP phosphodiesterase and amplifies hormone effects in hepatocytes and hepatoma cells.
Carcinoma, Hepatocellular
The involvement of cyclic GMP in tyrosine aminotransferase degradation in rat hepatoma tissue culture cells.
Carcinoma, Hepatocellular
The stimulation of cyclic nucleotide phosphodiesterase by a Mr 11 500 calcium binding protein from hepatoma.
Carcinoma, Hepatocellular
[Adenosine cyclic-3',5'-monophosphate phosphodiesterase in hepatomas with different growth rates]
Carcinoma, Hepatocellular
[Concentration and metabolism of cyclic AMP during the early stages of hepatoma 22a growth]
Carcinoma, Hepatocellular
[Some features of cyclic adenosine monophosphate metabolism in mouse liver and hepatoma 22]
Carcinoma, Lewis Lung
Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Carcinoma, Non-Small-Cell Lung
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking ?-catenin and MAPK signaling.
Carcinoma, Non-Small-Cell Lung
Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.
Carcinoma, Renal Cell
miR-5701 promoted apoptosis of clear cell renal cell carcinoma cells by targeting phosphodiesterase-1B.
Carcinoma, Renal Cell
Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Carcinoma, Squamous Cell
A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.
Carcinoma, Squamous Cell
Cyclic adenosine monophosphate-phosphodiesterase (cAMP-PDE) in lymphocytes from patients with stage III and IV squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells.
Carcinoma, Squamous Cell
PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Carcinoma, Squamous Cell
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Cardiac Output, Low
Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Cardiomegaly
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Cardiomegaly
C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
Cardiomegaly
Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2.
Cardiomegaly
Cardiac Overexpression of PDE4B Blunts ?-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Cardiomegaly
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Cardiomegaly
Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals.
Cardiomegaly
Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction.
Cardiomegaly
Role of Ca2+/Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy.
Cardiomyopathies
An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats.
Cardiomyopathies
Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice.
Cardiomyopathies
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Cardiomyopathy, Dilated
Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice.
Cardiomyopathy, Dilated
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.
Cardiomyopathy, Dilated
Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.
Cardiomyopathy, Dilated
Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.
Cardiotoxicity
A Multi-Protein Complex with TRPC, PDE1C, and A2R Plays a Critical Role in Regulating Cardiomyocyte cAMP and Survival.
Cardiovascular Diseases
Cardiovascular disease: PDE9A inhibition mends broken hearts.
Cardiovascular Diseases
Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?
Cardiovascular Diseases
Docking and quantitative structure-activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors.
Cardiovascular Diseases
E-pharmacophore based virtual screening for identification of dual specific PDE5A and PDE3A inhibitors as potential leads against cardiovascular diseases.
Cardiovascular Diseases
Multifunctional cationic Peptide fractions from flaxseed protein hydrolysates.
Cardiovascular Diseases
Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility.
Cardiovascular Diseases
Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals.
Cardiovascular Diseases
The importance of the NO-cGMP pathway in age-related cardiovascular disease: focus on phosphodiesterase-1 and soluble guanylate cyclise.
Cardiovascular Diseases
Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?
Carney Complex
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Carney Complex
[A pedigree study of a patient with primary pigmented nodular adrenocortical disease and familial gene mutation].
Carotid Artery Diseases
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Carotid Artery Thrombosis
Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A.
Catalepsy
Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy.
Catalepsy
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Catalepsy
Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Catalepsy
The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.
Central Nervous System Diseases
Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
Central Nervous System Diseases
Development of 2-(2-(3-(4-([18F]Fluoromethoxy-d2)phenyl)-7-methyl- 4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione for Positron Emission Tomography Imaging of Phosphodiesterase 10A (PDE10A) in Brain.
Central Nervous System Diseases
Discovery and Development of 11C-Lu AE92686 as a Radioligand for PET Imaging of Phosphodiesterase10A in the Brain.
Central Nervous System Diseases
Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject.
Cerebral Amyloid Angiopathy
Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages.
Cerebral Infarction
Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats.
Cerebral Infarction
Correlation between the single nucleotide polymorphisms of the human phosphodiesterase 4D gene and the risk of cerebral infarction in the Uygur and Han ethnic groups of Xinjiang, China.
Cerebral Infarction
Genotype and haplotype association study of the STRK1 region on 5q12 among Japanese: a case-control study.
Cerebral Infarction
K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.
Cerebral Infarction
Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations.
Cerebral Infarction
Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
Cerebrovascular Disorders
Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia.
Cerebrovascular Disorders
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.
Chagas Disease
Characterization of a novel cAMP-binding, cAMP-specific cyclic nucleotide phosphodiesterase (TcrPDEB1) from Trypanosoma cruzi.
Cholera
A hormone-independent rise of adenosine 3',5'-monophosphate desensitizes coupling of beta-adrenergic receptors to adenylate cyclase in rat glioma C6-cells.
Cholera
Calmodulin antagonists stimulate LDL receptor synthesis in human skin fibroblasts.
Cholera
Cyclic AMP increasing agents rapidly stimulate vimentin phosphorylation in quiescent cultures of Swiss 3T3 cells.
Cholera
Effects of cyclic adenosine 3':5'-monophosphate upon glycoprotein and carcinoembryonic antigen synthesis and release by human colon cancer cells.
Cholera
Increased cyclic AMP content directly correlated with morphological transformation of cells infected with a temperature-sensitive mutant of mouse sarcoma virus.
Cholera
Increases in cyclic AMP potentiate competence formation in BALB/c-3T3 cells.
Cholera
Involvement of cAMP in initiating maturation of the brittle-star Amphipholis kochii oocytes: induction of oocyte maturation by inhibitors of cyclic nucleotide phosphodiesterase and activators of adenylate cyclase.
Cholera
Muscarinic receptor-stimulated phosphoinositide turnover in human SK-N-SH neuroblastoma cells: differential inhibition by agents that elevate cyclic AMP.
Cholera
Potentiation of cholera toxin-stimulated cyclic AMP production in cultured cells by inhibitors of RNA and protein synthesis.
Cholera
Self-incompatibility involved in the level of acetylcholine and cAMP.
Cholera
Stimulation or endothelin-1 secretion by human breast cancer cells through protein kinase A activation: a possible novel paracrine loop involving breast fibroblast-derived prostaglandin E2.
Cholera
[Decrease in the lipid content of human atherosclerotic aorta cells as affected by compounds increasing the intracellular level of cyclic AMP]
Chondroma
Multiple endocrine neoplasias: advances and challenges for the future.
Chorea
A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea.
Chorea
A PDE10A de novo mutation causes childhood-onset chorea with diurnal fluctuations.
Chorea
Autoimmune movement disorders with neuronal antibodies - an update.
Chorea
Biallelic PDE2A variants: a new cause of syndromic paroxysmal dyskinesia.
Chorea
De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions.
Chorea
Familial choreoathetosis due to novel heterozygous mutation in PDE10A.
Chorea
The Emerging Role of Phosphodiesterases in Movement Disorders.
Cockayne Syndrome
Repair of persistent strand breaks in the mitochondrial genome.
Colitis
Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and ?-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice.
Colitis
Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation.
Colitis
Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway.
Colitis, Ulcerative
PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization.
Colonic Neoplasms
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Colonic Neoplasms
Cyclic phosphatidic acid stimulates cAMP production and inhibits growth in human colon cancer cells.
Colonic Neoplasms
Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.
Colonic Neoplasms
Glycerophosphodiester phosphodiesterase 1 (GDE1) acts as a potential tumor suppressor and is a novel therapeutic target for non-mucin-producing colon adenocarcinoma.
Colonic Neoplasms
Understanding h-prune biology in the fight against cancer.
Colorectal Neoplasms
?-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.
Colorectal Neoplasms
h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
Colorectal Neoplasms
Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation.
Colorectal Neoplasms
miR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D.
Colorectal Neoplasms
Parallel activation of cyclic AMP phosphodiesterase and cyclic AMP-dependent protein kinase in two human gut adenocarcinoma cells (HT 29 and HRT 18) in culture, by vasoactive intestinal peptide (VIP) and other effectors activating the cyclic AMP system.
Colorectal Neoplasms
Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer.
Colorectal Neoplasms
Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
Colorectal Neoplasms
Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
Coronary Artery Disease
Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease.
Coronary Artery Disease
Molecular genetics of coronary artery disease.
Coronary Artery Disease
Shear stress-induced MMP1 and PDE2A expressions in coronary atherosclerosis.
Coronary Disease
ENPP1 K121Q (rs1044498?C?>?A) genetic polymorphism confers a high risk of susceptibility to coronary heart disease: A PRISMA-compliant article.
Coronary Disease
PDE4D gene polymorphisms and coronary heart disease: a case-control study in a north Indian population.
Coronary Stenosis
Effect of Cilostazol, a Phosphodiesterase-3 Inhibitor, on Coronary Artery Stenosis and Plaque Characteristics in Patients with Type 2 Diabetes (ESCAPE Study).
Cough
Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity.
Cough
Phosphodiesterase 3 inhibition and cough in elderly asthmatics.
Cough
PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study.
Cough
Selective inhibitors for phosphodiesterase 3 and 4 in antigen-induced increase of cough reflex sensitivity in guinea pigs.
COVID-19
An epigenome-wide DNA methylation study of patients with COVID-19.
COVID-19
Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.
COVID-19
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.
COVID-19
Phosphodiesterase-3 Inhibitor Enoximone in SARS-CoV-2 Infection.
COVID-19
The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report.
Cushing Syndrome
A phosphodiesterase 11 (Pde11a) knockout mouse expressed functional but reduced Pde11a: Phenotype and impact on adrenocortical function.
Cushing Syndrome
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Cushing Syndrome
Carney complex and other conditions associated with micronodular adrenal hyperplasias.
Cushing Syndrome
Clinicopathological correlates of adrenal Cushing's syndrome.
Cushing Syndrome
Familial micronodular adrenocortical disease, Cushing syndrome, and mutations of the gene encoding phosphodiesterase 11A4 (PDE11A).
Cushing Syndrome
New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors.
Cushing Syndrome
[A pedigree study of a patient with primary pigmented nodular adrenocortical disease and familial gene mutation].
Cystic Fibrosis
Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.
Cystic Fibrosis
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis.
Cysts
PDE1A polymorphism contributes to the susceptibility of nephrolithiasis.
Cysts
Phosphodiesterase 1A Modulates Cystogenesis in Zebrafish.
Deafness
A dominant variant in the PDE1C gene is associated with nonsyndromic hearing loss.
Death, Sudden, Cardiac
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
Dementia
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.
Dementia
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Dementia
Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.
Dementia, Vascular
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia.
Dermatitis
Lymphocyte and monocyte localization of altered adrenergic receptors, cAMP responses, and cAMP phosphodiesterase in atopic dermatitis. A possible mechanism for abnormal radiosensitive helper T cells in atopic dermatitis.
Dermatitis, Atopic
Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis.
Dermatitis, Atopic
Apremilast: first global approval.
Dermatitis, Atopic
Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis.
Dermatitis, Atopic
Intracellular 3',5'-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis.
Dermatitis, Atopic
Lymphocyte and monocyte localization of altered adrenergic receptors, cAMP responses, and cAMP phosphodiesterase in atopic dermatitis. A possible mechanism for abnormal radiosensitive helper T cells in atopic dermatitis.
Dermatitis, Atopic
Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis.
Dermatitis, Atopic
Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro.
Dermatitis, Phototoxic
Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Diabetes Insipidus, Nephrogenic
ADH resistance of LLC-pk1 cells caused by overexpression of cAMP-phosphodiesterase type-IV.
Diabetes Insipidus, Nephrogenic
Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus.
Diabetes Mellitus
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Diabetes Mellitus
ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects.
Diabetes Mellitus
Impact of ENPP1 K121Q on change of insulin resistance after web-based intervention in Korean men with diabetes and impaired fasting glucose.
Diabetes Mellitus
Inhibitor of calmodulin and cAMP phosphodiesterase activity in BB rats.
Diabetes Mellitus
Osteoblast-specific deficiency of ectonucleotide pyrophosphatase or phosphodiesterase-1 engenders insulin resistance in high-fat diet fed mice.
Diabetes Mellitus
Phosphodiesterase 3 (PDE3) attenuates insulin secretion from the human pancreas: a specific PDE3 inhibitor improves insulin secretion in type II diabetes mellitus.
Diabetes Mellitus, Experimental
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia.
Diabetes Mellitus, Lipoatrophic
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus, Type 2
A selective phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control.
Diabetes Mellitus, Type 2
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study.
Diabetes Mellitus, Type 2
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.
Diabetes Mellitus, Type 2
Effect of Cilostazol, a Phosphodiesterase-3 Inhibitor, on Coronary Artery Stenosis and Plaque Characteristics in Patients with Type 2 Diabetes (ESCAPE Study).
Diabetes Mellitus, Type 2
ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects.
Diabetes Mellitus, Type 2
Impact of ENPP1 K121Q on change of insulin resistance after web-based intervention in Korean men with diabetes and impaired fasting glucose.
Diabetes Mellitus, Type 2
Liposomal delivery of a phosphodiesterase 3 inhibitor rescues low oxygen-induced ATP release from erythrocytes of humans with type 2 diabetes.
Diabetes Mellitus, Type 2
Osteoblast-specific deficiency of ectonucleotide pyrophosphatase or phosphodiesterase-1 engenders insulin resistance in high-fat diet fed mice.
Diabetes Mellitus, Type 2
Phosphodiesterase 3B is localized in caveolae and smooth ER in mouse hepatocytes and is important in the regulation of glucose and lipid metabolism.
Diabetes Mellitus, Type 2
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Diabetes Mellitus, Type 2
Systematic search for single nucleotide polymorphisms in the 5' flanking region of the human phosphodiesterase 3B gene: absence of evidence for major effects of identified polymorphisms on susceptibility to Japanese type 2 diabetes.
Diabetes Mellitus, Type 2
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Diabetes Mellitus, Type 2
The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes and related metabolic traits in an Iranian population.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes in northern Chinese.
Diabetic Angiopathies
Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats.
Down Syndrome
Cilostazol, a Phosphodiesterase 3 Inhibitor, Moderately Attenuates Behaviors Depending on Sex in the Ts65Dn Mouse Model of Down Syndrome.
Down Syndrome
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Dyskinesias
A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys.
Dyskinesias
A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
Dyskinesias
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Dyskinesias
Emerging Monogenic Complex Hyperkinetic Disorders.
Dyskinesias
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
Dyskinesias
Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Dyslipidemias
Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis.
Dystonia
Emerging Monogenic Complex Hyperkinetic Disorders.
Dystonia
Frameless robot-assisted pallidal deep brain stimulation surgery in pediatric patients with movement disorders: precision and short-term clinical results.
Dystonia
Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
Eczema
Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy.
Embolic Stroke
Association of Phosphodiesterase 4D with ischemic stroke: a population-based case-control study.
Embolic Stroke
Effects of PDE4 pathway inhibition in rat experimental stroke.
Embolic Stroke
Phosphodiesterase4D (PDE4D)--A risk factor for atrial fibrillation and stroke?
Encephalitis
Papaverine ameliorates prenatal alcohol-induced experimental attention deficit hyperactivity disorder by regulating neuronal function, inflammation, and oxidative stress.
Encephalitis
PDE10A antibodies in autoimmune encephalitis: A possible marker of cancer immunotherapy?
Encephalomyelitis
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Encephalomyelitis
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.
Endolymphatic Hydrops
Inhibition of phosphodiesterase 3, 4, and 5 induces endolymphatic hydrops in mouse inner ear, as evaluated with repeated 9.4T MRI.
Eosinophilia
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs.
Epilepsy
Biallelic PDE2A variants: a new cause of syndromic paroxysmal dyskinesia.
Epilepsy
The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities.
Epilepsy, Temporal Lobe
The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities.
Erectile Dysfunction
3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.
Erectile Dysfunction
Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5).
Erectile Dysfunction
Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis.
Erectile Dysfunction
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.
Erectile Dysfunction
Molecular biological characterization of phosphodiesterase 3A from human corpus cavernosum.
Erectile Dysfunction
Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability.
Erectile Dysfunction
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Erectile Dysfunction
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
Esophageal Squamous Cell Carcinoma
h-prune Is an Independent Prognostic Marker for Survival in Esophageal Squamous Cell Carcinoma.
Fatty Liver
Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis.
Fatty Liver
Phosphodiesterase 3B is localized in caveolae and smooth ER in mouse hepatocytes and is important in the regulation of glucose and lipid metabolism.
Fragile X Syndrome
Correction to: The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome.
Fragile X Syndrome
Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Fragile X Syndrome
The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome.
Ganglioneuroma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Gastrointestinal Stromal Tumors
Multiple endocrine neoplasias: advances and challenges for the future.
Gastrointestinal Stromal Tumors
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Gastrointestinal Stromal Tumors
Targeting tumor cells based on Phosphodiesterase 3A expression.
Genetic Diseases, Inborn
Isolation and characterization of a human chromosome 21q22.3 gene (WDR4) and its mouse homologue that code for a WD-repeat protein.
Genetic Diseases, Inborn
Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
Giardiasis
[Comparative efficacy of tiniba and fasigyn in treating primary and persisting Giardia infections]
Glioblastoma
Calmodulin-dependent cyclic nucleotide phosphodiesterase in human cerebral cortex and glioblastoma multiforme.
Glioblastoma
Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
Glioblastoma
Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiforme cells in vitro.
Glioblastoma
Differential phosphodiesterase expression and cytosolic Ca2+ in human CNS tumour cells and in non-malignant and malignant cells of rat origin.
Glioblastoma
Identification of novel genetic alterations in samples of malignant glioma patients.
Glioblastoma
Novel protein inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase from glioblastoma multiforme.
Glioblastoma
Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells.
Glioma
beta Adrenergic receptor-mediated regulation of cyclic nucleotide phosphodiesterase in C6 glioma cells: vinblastine blockade of isoproterenol induction.
Glioma
Cyclic AMP-mediated induction of ornithine decarboxylase of glioma and neuroblastoma cells.
Glioma
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Glioma
Identification of novel genetic alterations in samples of malignant glioma patients.
Glioma
miR-139/PDE2A-Notch1 feedback circuit represses stemness of gliomas by inhibiting Wnt/?-catenin signaling.
Glioma
Neurite formation in NG108-15 neuroblastoma x glioma hybrid cells by KS-505a, a potent inhibitor of brain cyclic nucleotide phosphodiesterase.
Glioma
New opportunities with neuronal cultures to study the mechanisms of neurotoxic injuries.
Glioma
Regulation by a beta-adrenergic receptor of a Ca2+-independent adenosine 3',5'-(cyclic)monophosphate phosphodiesterase in C6 glioma cells.
Glioma
RNA polymerase II in C6 glioma cells. Alpha-amanitin blockade of cAMP phosphodiesterase induction by beta-adrenergic stimulation.
Glioma
Transient increase in intracellular concentration of adenosine 3':5'-cyclic monophosphate results in morphological and biochemical differentiation of C6 glioma cells in culture.
Gliosarcoma
Novel protein inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase from glioblastoma multiforme.
Glomerulonephritis
Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV.
Glucose Intolerance
Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology.
Glucose Intolerance
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins.
Head and Neck Neoplasms
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Hearing Loss
A dominant variant in the PDE1C gene is associated with nonsyndromic hearing loss.
Heart Defects, Congenital
Critical role of Phosphodiesterase 2A in mouse congenital heart defects.
Heart Diseases
A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.
Heart Diseases
An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.
Heart Diseases
C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
Heart Diseases
cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.
Heart Diseases
Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.
Heart Diseases
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Heart Diseases
Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload.
Heart Diseases
Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Heart Failure
A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.
Heart Failure
Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.
Heart Failure
Amrinone suppresses the synthesis of tumor necrosis factor-alpha in human mononuclear cells.
Heart Failure
Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate.
Heart Failure
Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure.
Heart Failure
Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.
Heart Failure
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
Heart Failure
Cardiohemodynamic and electrophysiological effects of a selective EP4 receptor agonist ONO--AE1--329 in the halothane-anesthetized dogs.
Heart Failure
Cardiopulmonary effects of phosphine poisoning: A preliminary evaluation of milrinone.
Heart Failure
Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.
Heart Failure
Comparing the effects of milrinone and olprinone in patients with congestive heart failure.
Heart Failure
Determinants of In-Hospital Mortality in Elderly Patients Aged 80 Years or above with Acute Heart Failure: A Retrospective Cohort Study at a Single Rural Hospital.
Heart Failure
Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues.
Heart Failure
From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.
Heart Failure
Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure.
Heart Failure
Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure.
Heart Failure
In vivo Dilatation of the Fetal and Postnatal Ductus Arteriosus by Inhibition of Phosphodiesterase 3 in Rats.
Heart Failure
Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure.
Heart Failure
Inhibiting Insulin-Mediated ?2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.
Heart Failure
Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Heart Failure
Phosphodiesterase 2 as a Therapeutic Target for Heart Failure: Is Upregulation an Option?
Heart Failure
Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure.
Heart Failure
Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction.
Heart Failure
Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure.
Heart Failure
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Heart Failure
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Heart Failure
Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction.
Heart Failure
Phosphodiesterase-2 is Upregulated in Human Failing Hearts and Blunts ?-Adrenergic Responses in Cardiomyocytes.
Heart Failure
Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.
Heart Failure
Regulation of Sarcoplasmic Reticulum Ca2+ ATPase 2 (SERCA2) Activity by Phosphodiesterase 3A (PDE3A) in Human Myocardium: PHOSPHORYLATION-DEPENDENT INTERACTION OF PDE3A1 WITH SERCA2.
Heart Failure
Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms.
Heart Failure
Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.
Heart Failure
[Novel types of cardiotonic drugs]
Heart Failure
[Tendency of development on novel type of cardiotonic drugs]
Heart Failure, Systolic
Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure.
Hematologic Neoplasms
PDE4 subtypes in cancer.
Hemorrhagic Stroke
Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier.
Hepatitis B
Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2.
Herpes Zoster
High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells.
Herpes Zoster
Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species.
Herpes Zoster
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism.
HIV Infections
HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor.
Hodgkin Disease
Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin's disease lymphocytes.
Huntington Disease
?-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.
Huntington Disease
A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor.
Huntington Disease
Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
Huntington Disease
AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.
Huntington Disease
Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [(11) C]T-773 in nonhuman primates.
Huntington Disease
Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Huntington Disease
Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
Huntington Disease
Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
Huntington Disease
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
Huntington Disease
Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Huntington Disease
Chronic suppression of PDE10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission and signaling pathways implicated in Huntington's Disease.
Huntington Disease
Comparison of Phosphodiesterase 10A, Dopamine Receptors D1 and D2 and Dopamine Transporter Ligand Binding in the Striatum of the R6/2 and BACHD Mouse Models of Huntington's Disease.
Huntington Disease
Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Huntington Disease
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Huntington Disease
Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.
Huntington Disease
Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
Huntington Disease
Emerging biology of PDE10A.
Huntington Disease
Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging.
Huntington Disease
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Huntington Disease
Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches.
Huntington Disease
Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.
Huntington Disease
Molecular Imaging of PDE10A Knockout Mice with a Novel PET Radiotracer: [(11)C]T-773.
Huntington Disease
MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease.
Huntington Disease
N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
Huntington Disease
PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
Huntington Disease
PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.
Huntington Disease
PET imaging shows loss of striatal PDE10A in patients with Huntington disease.
Huntington Disease
PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression.
Huntington Disease
Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
Huntington Disease
Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Huntington Disease
Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.
Huntington Disease
Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Huntington Disease
Phosphodiesterases in neurodegenerative disorders.
Huntington Disease
Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A.
Huntington Disease
Role of phosphodiesterases in neurological and psychiatric disease.
Huntington Disease
Structure-Based Design of Scaffolds Targeting PDE10A by INPHARMA-NMR.
Huntington Disease
Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.
Huntington Disease
TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Huntington Disease
The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
Huntington Disease
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Hydrocephalus
Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination.
Hydrocephalus
Phosphodiesterase 1A Modulates Cystogenesis in Zebrafish.
Hyperaldosteronism
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism.
Hyperalgesia
Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone.
Hyperalgesia
Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.
Hypercalcemia
AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Hyperglycemia
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Hyperinsulinism
Inhibiting Insulin-Mediated ?2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.
Hyperkinesis
Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
Hyperkinesis
Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Hyperkinesis
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Hyperkinesis
PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.
Hyperkinesis
Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Hypersensitivity
Effects of MKS-492 on antigen-induced bronchoconstriction and allergic reaction in guinea pigs and rats.
Hypersensitivity
Neonatal leukocyte cAMP-phosphodiesterase determination is not suitable for allergy prediction.
Hypersensitivity
The High-Affinity cAMP-Specific Phosphodiesterase 8B Controls Steroidogenesis in the Mouse Adrenal Gland.
Hypertension
A PDE3A mutation in familial hypertension and brachydactyly syndrome.
Hypertension
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Hypertension
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Hypertension
Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12.
Hypertension
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Hypertension
Current Nomenclature of Pseudohypoparathyroidism: Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Protein Signaling Disorder.
Hypertension
Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension.
Hypertension
Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells.
Hypertension
Emerging Role of Phosphodiesterase 2A in Hypertension.
Hypertension
Hypertension and brachydactyly syndrome associated with vertebral artery malformation caused by a PDE3A missense mutation.
Hypertension
Hypertension linked to PDE3A activation.
Hypertension
Local cyclic adenosine monophosphate signalling cascades-Roles and targets in chronic kidney disease.
Hypertension
PDE3A gene screening improves diagnostics for patients with Bilginturan syndrome (hypertension and brachydactyly syndrome).
Hypertension
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Hypertension
PDE3A variant associated with hypertension and brachydactyly syndrome in a patient with ischemic stroke caused by spontaneous intracranial artery dissection: A review of the clinical and molecular genetic features.
Hypertension
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
Hypertension
Phosphodiesterase 3A and Arterial Hypertension.
Hypertension
Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population.
Hypertension
Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation.
Hypertension
Whole-exome sequencing identifies a de novo PDE3A variant causing autosomal dominant hypertension with brachydactyly type E syndrome: a case report.
Hypertension
[Association between mRNA level of Pde4d and Alox5ap and hypertensive stroke as well as hypertension in rats.]
Hypertension
[Phosphodiesterase characteristics of the fat cells in spontaneous hypertension in rats]
Hypertension, Pulmonary
A comparison of the spasmolytic effects of olprinone and aminophylline on serotonin-induced pulmonary hypertension and bronchoconstriction with or without beta-blockade in dogs.
Hypertension, Pulmonary
Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Hypertension, Pulmonary
Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
Hypertension, Pulmonary
Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1.
Hypertension, Pulmonary
Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure.
Hypertension, Pulmonary
Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension.
Hypertension, Pulmonary
Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.
Hypertension, Pulmonary
Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension.
Hypertension, Pulmonary
Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry.
Hypertension, Pulmonary
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Hyperthyroidism
Adenosine deaminase inhibition enhances the inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium.
Hyperthyroidism
Effects of thyroid hormone on regulation of lipolysis and adenosine 3',5'-monophosphate metabolism in 3T3-L1 adipocytes.
Hyperthyroidism
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Hyperthyroidism
Positive inotropic effect of the inhibition of cyclic GMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase (PDE2) on guinea pig left atria in eu- and hyperthyroidism.
Hyperthyroidism
The atrial natriuretic peptide- and catecholamine-induced lipolysis and expression of related genes in adipose tissue in hypothyroid and hyperthyroid patients.
Hypoglycemia
Importance of phosphodiesterase 3 for the lipolytic response in adipose tissue during insulin-induced hypoglycemia in normal man.
Hypokinesia
Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
Hypophosphatasia
Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders.
Hypophosphatasia
Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice.
Hypotension
Efficacy of Cilostazol in Prevention of Bradycardia during Carotid Artery Stenting.
Hypotension
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.
Hypotension
Olprinone/dopamine combination for improving diaphragmatic fatigue in pentobarbital-anesthetized dogs.
Hypothyroidism
Novel associations for hypothyroidism include known autoimmune risk loci.
Hypothyroidism
Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy.
Hypothyroidism
Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a Genetics of Diabetes Audit and Research Tayside study (GoDARTS).
Idiopathic Pulmonary Fibrosis
Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.
Infarction, Middle Cerebral Artery
Homozygous Smpd1 deficiency aggravates brain ischemia/ reperfusion injury by mechanisms involving polymorphonuclear neutrophils, whereas heterozygous Smpd1 deficiency protects against mild focal cerebral ischemia.
Infections
Adenovirus-mediated overexpression of murine cyclic nucleotide phosphodiesterase 3B.
Infections
Allele-Specific Expression of CD4+ T Cells in Response to Marek's Disease Virus Infection.
Infections
Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-?B signaling.
Infections
Effects of TDP2/VPg Unlinkase Activity on Picornavirus Infections Downstream of Virus Translation.
Infections
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Infections
Lentiviral-Mediated shRNA Silencing of PDE4D Gene Inhibits Platelet-Derived Growth Factor-Induced Proliferation and Migration of Rat Aortic Smooth Muscle Cells.
Infections
Role of cAMP Signaling in the Survival and Infectivity of the Protozoan Parasite, Leishmania donovani.
Infections
TRI6 and TRI10 play different roles in the regulation of DON production by cAMP signaling in Fusarium graminearum.
Infertility
Infertility and male mating behavior deficits associated with Pde1c in Drosophila melanogaster.
Infertility
Phosphodiesterase 8B Polymorphism rs4704397 Is Associated with Infertility in Subclinical Hypothyroid Females: A Case-Control Study.
Infertility
Reduction in the intracellular cAMP level triggers initiation of sexual development in fission yeast.
Infertility
Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility.
Infertility, Female
Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.
Infertility, Female
Generation of mouse oocytes defective in cAMP synthesis and degradation: endogenous cyclic AMP is essential for meiotic arrest.
Infertility, Male
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Infertility, Male
Infertility and male mating behavior deficits associated with Pde1c in Drosophila melanogaster.
Infertility, Male
Pde8b haploinsufficiency in mice is associated with modest adrenal defects, impaired steroidogenesis, and male infertility, unaltered by concurrent PKA or Wnt activation.
Insulin Resistance
A novel thermoregulatory role for PDE10A in mouse and human adipocytes.
Insulin Resistance
Activation of mouse phosphodiesterase 3B gene promoter by adipocyte differentiation in 3T3-L1 cells.
Insulin Resistance
Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse.
Insulin Resistance
Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice.
Insulin Resistance
C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes.
Insulin Resistance
Cognitive deficits associated with a high-fat diet and insulin resistance are potentiated by overexpression of Ecto-nucleotide pyrophosphatase phosphodiesterase-1.
Insulin Resistance
Cyclic nucleotide phosphodiesterases in pancreatic islets.
Insulin Resistance
Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP.
Insulin Resistance
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Insulin Resistance
Genetic Deletion and Pharmacological Inhibition of PDE10A Protects Mice from Diet-Induced Obesity and Insulin Resistance.
Insulin Resistance
Hypothalamic PDE3B deficiency alters body weight and glucose homeostasis in mouse
Insulin Resistance
Impact of ENPP1 K121Q on change of insulin resistance after web-based intervention in Korean men with diabetes and impaired fasting glucose.
Insulin Resistance
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
Insulin Resistance
Inactivation of NF-?B p65 (RelA) in Liver Improves Insulin Sensitivity and Inhibits cAMP/PKA Pathway.
Insulin Resistance
Insulin-sensitive adenosine 3',5'-cyclic monophosphate phosphodiesterase of hepatocyte plasma membrane.
Insulin Resistance
Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.
Insulin Resistance
Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance.
Insulin Resistance
Osteoblast-specific deficiency of ectonucleotide pyrophosphatase or phosphodiesterase-1 engenders insulin resistance in high-fat diet fed mice.
Insulin Resistance
Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse.
Insulin Resistance
Studies of insulin resistance in the streptozotocin diabetic and BB rat: activation of low Km cAMP phosphodiesterase by insulin.
Insulin Resistance
Systematic search for single nucleotide polymorphisms in the 5' flanking region of the human phosphodiesterase 3B gene: absence of evidence for major effects of identified polymorphisms on susceptibility to Japanese type 2 diabetes.
Insulin Resistance
Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
Insulin Resistance
The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects.
Insulin Resistance
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes and related metabolic traits in an Iranian population.
Insulin Resistance
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes in northern Chinese.
Insulin Resistance
The K121Q polymorphism of ENPP1 and peripheral arterial disease.
Insulin Resistance
The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities.
Insulinoma
Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin.
Insulinoma
The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
Intellectual Disability
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Intellectual Disability
Different mutations in PDE4D associated with developmental disorders with mirror phenotypes.
Intellectual Disability
Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis.
Intellectual Disability
Expanding the phenotypic spectrum of variants in PDE4D/PRKAR1A: from acrodysostosis to acroscyphodysplasia.
Intellectual Disability
Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
Intermittent Claudication
Cerebrovascular effects of cilostazol in patients with atherosclerotic disease.
Intermittent Claudication
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Intermittent Claudication
Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Intermittent Claudication
Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity.
Intermittent Claudication
Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-kappaB inactivation: not involved in cAMP mechanisms.
Intermittent Claudication
Cilostazol Stimulates Revascularisation in Response to Ischaemia via an eNOS-Dependent Mechanism.
Intermittent Claudication
Cilostazol: improving walking distance in patients with intermittent claudication.
Intermittent Claudication
Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Intermittent Claudication
Effect of cilostazol in treating diabetes-associated microvascular complications.
Intermittent Claudication
Effects of cilostazol in the heart.
Intermittent Claudication
Effects of Cilostazol on arterial wound healing: a retrospective analysis.
Intermittent Claudication
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Intermittent Claudication
K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.
Intermittent Claudication
Role of Nrf2/HO-1 and PI3K/AKT Genes In The Hepatoprotective Effect of cilostazol.
Intervertebral Disc Displacement
Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.
Ischemic Attack, Transient
Sequential alterations of [3H]rolipram and [3H]cyclic adenosine monophosphate binding in the gerbil brain following transient cerebral ischemia.
Ischemic Stroke
A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene.
Ischemic Stroke
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Ischemic Stroke
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Ischemic Stroke
Advances in the genetic basis of coronary artery disease.
Ischemic Stroke
Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Ischemic Stroke
Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke.
Ischemic Stroke
Association between PDE4D gene and ischemic stroke: recent advancements.
Ischemic Stroke
Association between PDE4D polymorphism and ischemic stroke in young population.
Ischemic Stroke
Association between PDE4D rs966221 polymorphism and risk of ischemic stroke: a systematic review and meta-analysis.
Ischemic Stroke
Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis.
Ischemic Stroke
Association between phosphodiesterase 4D gene and ischaemic stroke.
Ischemic Stroke
Association between phosphodiesterase 4D polymorphism SNP83 and ischemic stroke.
Ischemic Stroke
Association between the PDE4D gene and ischemic stroke in Han Chinese population.
Ischemic Stroke
Association of GWAS-susceptibility loci with ischemic stroke recurrence in a Han Chinese population.
Ischemic Stroke
Association of PDE4D and IL-1 gene polymorphism with ischemic stroke in a Han Chinese population.
Ischemic Stroke
Association of PDE4D gene with ischaemic stroke.
Ischemic Stroke
Association of phosphodiesterase 4D gene and interleukin-6 receptor gene polymorphisms with ischemic stroke in a Chinese hypertensive population.
Ischemic Stroke
Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population.
Ischemic Stroke
Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population.
Ischemic Stroke
Association of Phosphodiesterase 4D with ischemic stroke: a population-based case-control study.
Ischemic Stroke
Association of SNP41, SNP56 and a novel SNP in PDE4D gene with stroke and its subtypes.
Ischemic Stroke
Cilostazol for secondary stroke prevention: systematic review and meta-analysis.
Ischemic Stroke
Effects of PDE4 pathway inhibition in rat experimental stroke.
Ischemic Stroke
Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages.
Ischemic Stroke
Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.
Ischemic Stroke
Familial aggregation, the PDE4D gene, and ischemic stroke in a genetically isolated population.
Ischemic Stroke
Genetic polymorphism in PDE4D gene and risk of ischemic stroke in Chinese population: a meta-analysis.
Ischemic Stroke
Genetics of ischemic stroke: Indian perspective.
Ischemic Stroke
Impact of the PDE4D gene polymorphism and additional SNP-SNP and gene-smoking interaction on ischemic stroke risk in Chinese Han population.
Ischemic Stroke
Inflammatory system gene polymorphism and the risk of stroke: a case-control study in an Indian population.
Ischemic Stroke
Influence of Genetic Variation in PDE3A on Endothelial Function and Stroke.
Ischemic Stroke
Interaction between CONNEXIN37 and PDE4D gene polymorphisms with susceptibility to ischemic stroke in Chinese population.
Ischemic Stroke
Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region.
Ischemic Stroke
Ischemic stroke risk in a southeastern Chinese population: Insights from 5-lipoxygenase activating protein and phosphodiesterase 4D single-nucleotide polymorphisms.
Ischemic Stroke
Lack of association between variations of PDE4D and ischemic stroke in the Japanese population.
Ischemic Stroke
Lentiviral-Mediated shRNA Silencing of PDE4D Gene Inhibits Platelet-Derived Growth Factor-Induced Proliferation and Migration of Rat Aortic Smooth Muscle Cells.
Ischemic Stroke
Linkage of ischemic stroke to the PDE4D region on 5q in a Swedish population.
Ischemic Stroke
Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations.
Ischemic Stroke
Meta-Analysis of Homogeneous Subgroups Reveals Association between PDE4D Gene Variants and Ischemic Stroke.
Ischemic Stroke
Molecular genetics of coronary artery disease.
Ischemic Stroke
Multilocus Bayesian meta-analysis of gene-disease associations.
Ischemic Stroke
Neuroinflammation in Ischemic Stroke: Inhibition of cAMP-Specific Phosphodiesterases (PDEs) to the Rescue.
Ischemic Stroke
No Association Between Single-Nucleotide Polymorphism 56 (SNP56) in Phosphodiesterase 4D (PDE4D) Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies.
Ischemic Stroke
No Association Between SNP56 in PDE4D Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies.
Ischemic Stroke
PDE3A variant associated with hypertension and brachydactyly syndrome in a patient with ischemic stroke caused by spontaneous intracranial artery dissection: A review of the clinical and molecular genetic features.
Ischemic Stroke
PDE4D gene in the STRK1 region on 5q12: susceptibility gene for ischemic stroke.
Ischemic Stroke
Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.
Ischemic Stroke
Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population.
Ischemic Stroke
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Ischemic Stroke
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Ischemic Stroke
Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke.
Ischemic Stroke
Phosphodiesterase 4D Single Nucleotide Polymorphism 83 and Cognitive Dysfunction in Carotid Endarterectomy Patients.
Ischemic Stroke
Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.
Ischemic Stroke
Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation.
Ischemic Stroke
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Ischemic Stroke
The Siblings With Ischemic Stroke Study (SWISS): A Progress Report.
Ischemic Stroke
Variation in the PDE4D gene and ischemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls.
Ischemic Stroke
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol.
Ischemic Stroke
[A clinical and genetic analysis of risk factors for the development of acute and chronic cerebral ischemia].
Ischemic Stroke
[Analysis of the polymorphic variants of the PDE4D gene in patients with acute stroke in the Moldavian population].
Ischemic Stroke
[Association study between PDE4D gene polymorphism and ischemic stroke].
Ischemic Stroke
[Association study of polymorphic markers of F12, PON1, PON2, NOS2, PDE4D, HIF1a, GPIba, CYP11B2 genes with ischemic stroke in Russian patients].
Ischemic Stroke
[Multilocus analysis of the association of polymorphic variants of inflammation genes with ischemic stroke in Russians].
Ischemic Stroke
Investigation of single nucleotide polymorphisms in phosphodiesterase 4D gene in Mongol and Han patients with ischemic stroke in Inner Mongolia.
Leukemia
Cationic anticancer drugs and their modes of action.
Leukemia
PDE8 controls CD4(+) T cell motility through the PDE8A-Raf-1 kinase signaling complex.
Leukemia
[Phosphatidylethanolamine methylase and cyclic nucleotide phosphodiesterase activities in human B lymphoid hemopathies]
Leukemia L1210
Cationic anticancer drugs and their modes of action.
Leukemia, Erythroblastic, Acute
Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis.
Leukemia, Erythroblastic, Acute
Inhibitory effects of theophylline and dibutyryl cAMP on murine erythroleukemia cell differentiation.
Leukemia, Erythroblastic, Acute
Isolation and regulation of the cGMP-inhibited cAMP phosphodiesterase in human erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Regulation of cyclic 3',5'-adenosine monophosphate phosphodiesterase in Friend erythroleukemia cells.
Leukemia, Hairy Cell
[Phosphatidylethanolamine methylase and cyclic nucleotide phosphodiesterase activities in human B lymphoid hemopathies]
Leukemia, Lymphocytic, Chronic, B-Cell
Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Leukemia, Lymphocytic, Chronic, B-Cell
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
Leukemia, Lymphocytic, Chronic, B-Cell
Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Leukemia, Lymphocytic, Chronic, B-Cell
[Phosphatidylethanolamine methylase and cyclic nucleotide phosphodiesterase activities in human B lymphoid hemopathies]
Leukemia, Lymphoid
Cyclic AMP phosphodiesterase in human lymphocytes and lymphoblasts.
Leukemia, Myeloid, Acute
LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles.
Liver Diseases
Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis.
Liver Diseases
Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins.
Liver Diseases
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Diseases, Alcoholic
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Lung Injury
Inhibition of HA synthase 3 mRNA expression, with a phosphodiesterase 3 inhibitor, blocks lung injury in a septic ventilated rat model.
Lung Injury
Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury.
Lung Neoplasms
H-Prune through GSK-3? interaction sustains canonical WNT/?-catenin signaling enhancing cancer progression in NSCLC.
Lung Neoplasms
Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D.
Lung Neoplasms
PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Lung Neoplasms
PDE4 subtypes in cancer.
Lung Neoplasms
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking ?-catenin and MAPK signaling.
Lung Neoplasms
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Lung Neoplasms
Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.
Lung Neoplasms
Structure-based identification of dual ligands at the A2AR and PDE10A with anti-proliferative effects in lung cancer cell-lines.
Lung Neoplasms
The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.
Lupus Erythematosus, Systemic
Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes.
Lymphatic Metastasis
h-prune affects anaplastic thyroid cancer invasion and metastasis.
Lymphatic Metastasis
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Lymphoma
A lymphomagenic role for HIV beyond immune suppression?
Lymphoma
A structural gene mutation affecting the regulatory subunit of cyclic AMP-dependent protein kinase in mouse lymphoma cells.
Lymphoma
Adenylate cyclase permanently uncoupled from hormone receptors in a novel variant of S49 mouse lymphoma cells.
Lymphoma
Cyclic AMP-induced cytolysis in S49 cells: selection of an unresponsive "deathless" mutant.
Lymphoma
High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.
Lymphoma
Increased cyclic nucleotide phosphodiesterase activity in a mutant S49 lymphoma cell. Characterization and comparison with wild type enzyme activity.
Lymphoma
Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.
Lymphoma
Regulation of phosphodiesterase and ornithine decarboxylase by cAMP is cell cycle independent.
Lymphoma
Serum-stimulated cyclic-AMP production in S49 lymphoma cells grown in serum-free medium.
Lymphoma
[Expression of Cyclic Nucleotide Phosphodiesterase 7B in Patients with Mantle Cell Lymphoma and Its Prognostic Significance.]
Lymphoma
[Phosphatidylethanolamine methylase and cyclic nucleotide phosphodiesterase activities in human B lymphoid hemopathies]
Lymphoma, Mantle-Cell
High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.
Lymphoma, Mantle-Cell
[Expression of Cyclic Nucleotide Phosphodiesterase 7B in Patients with Mantle Cell Lymphoma and Its Prognostic Significance.]
Malformations of Cortical Development, Group II
A balanced de novo inv(7)(p14.3q22.3) disrupting PDE1C and ATXN7L1 in a 14-year old developmentally delayed boy.
Medulloblastoma
Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma.
Melanoma
3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Melanoma
Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1.
Melanoma
Associations between smoking behavior-related alleles and the risk of melanoma.
Melanoma
Characterization of phosphodiesterase 1 in human malignant melanoma cell lines.
Melanoma
Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.
Melanoma
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Melanoma
Debenzylative Cycloetherification as a Synthetic Tool in the Diastereoselective Synthesis of 3,6-Disubstituted Hexahydro-2H-furo[3,2-b]pyrroles, PDE1 Enzyme Inhibitors with an Antiproliferative Effect on Melanoma Cells.
Melanoma
Decreased expressions of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture.
Melanoma
Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cells.
Melanoma
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
Melanoma
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Melanoma
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
Melanoma
PRESM: Personalized Reference Editor for Somatic Mutation discovery in cancer genomics.
Melanoma
Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
Melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Melanoma, Amelanotic
Effect of sodium butyrate in combination with prostaglandin E1 and inhibitors of cyclic nucleotide phosphodiesterase on human amelanotic melanoma cells in culture.
Melanoma, Experimental
Properties of acidic saccharides produced by B16 melanoma cells treated with 1-methyl-3-isobutylxanthine.
Memory Disorders
Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway.
Memory Disorders
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.
Memory Disorders
Identification and molecular characterization of a novel PDE4D11 cAMP-specific phosphodiesterase isoform.
Memory Disorders
New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.
Memory Disorders
Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion.
Memory Disorders
Phosphodiesterase-4D Knockdown in the Prefrontal Cortex Alleviates Memory Deficits and Synaptic Failure in Mouse Model of Alzheimer's Disease.
Memory Disorders
RNA Interference-Mediated Knockdown of Long-Form Phosphodiesterase-4D (PDE4D) Enzyme Reverses Amyloid-?42-Induced Memory Deficits in Mice.
Memory Disorders
Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat.
Mouth Neoplasms
Metabolic Regulation of Glycolysis and AMP Activated Protein Kinase Pathways during Black Raspberry-Mediated Oral Cancer Chemoprevention.
Mouth Neoplasms
MicroRNA-133 Targets Phosphodiesterase 1C in Drosophila and Human Oral Cancer Cells to Regulate Epithelial-Mesenchymal Transition.
Movement Disorders
A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea.
Movement Disorders
A novel mutation of PDE8B Gene in a Japanese family with autosomal-dominant striatal degeneration.
Movement Disorders
A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
Movement Disorders
Autosomal-dominant striatal degeneration is caused by a mutation in the phosphodiesterase 8B gene.
Movement Disorders
Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
Movement Disorders
Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Movement Disorders
Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
Movement Disorders
Emerging biology of PDE10A.
Movement Disorders
PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.
Movement Disorders
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Movement Disorders
PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.
Movement Disorders
PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression.
Movement Disorders
Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Movement Disorders
Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.
Movement Disorders
The Emerging Role of Phosphodiesterases in Movement Disorders.
Multiple Sclerosis
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Muscular Atrophy
Mechanisms Involved in 3',5'-Cyclic Adenosine Monophosphate-Mediated Inhibition of the Ubiquitin-Proteasome System in Skeletal Muscle.
Muscular Dystrophies
Adenyl cyclase and cyclic nucleotide phosphodiesterase activities in murine muscular dystrophy.
Muscular Dystrophies
PDE10A Inhibition Reduces the Manifestation of Pathology in DMD Zebrafish and Represses the Genetic Modifier PITPNA.
Myalgia
Underlying mechanisms of phosphodiesterase 10A and glutamate-ammonia ligase genes that regulate inosine monophosphate deposition and thereby affect muscle tenderness in Jingyuan chickens.
Myocardial Infarction
Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
Myocardial Infarction
Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts.
Myocardial Infarction
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.
Myocardial Infarction
Molecular genetics of coronary artery disease.
Myocardial Infarction
Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction.
Myocardial Infarction
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Myocardial Infarction
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Myocardial Infarction
Role of FLAP and PDE4D in Myocardial Infarction and Stroke: Target Discovery and Future Treatment Options.
Myocardial Infarction
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Myocardial Infarction
Studies on plasma cyclic nucleotide, cyclic nucleotide phosphodiesterase, beta-thromboglobulin, and myoglobin response in patients with acute myocardial infarction.
Myocardial Infarction
The K121Q polymorphism of ENPP1 and peripheral arterial disease.
Myocardial Infarction
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol.
Myocardial Ischemia
Effect of isometric handgrip on systolic time intervals in patients with ischemic heart disease and cyclic amp phosphodiesterase inhibitor pretreatment.
Myoma
[Peptide-activator of cyclic nucleotide phosphodiesterases in the rat and human uterus]
Myopia
Genome-Wide Association of Genetic Variants With Refraction, Axial Length, and Corneal Curvature: A Longitudinal Study of Chinese Schoolchildren.
Nasal Polyps
Evaluation of patients with nasal polyps about the possible association of desmosomal junctions, RORA and PDE4D gene.
Nasopharyngeal Carcinoma
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Neoplasm Metastasis
Domain mapping on the human metastasis regulator protein h-Prune reveals a C-terminal dimerization domain.
Neoplasm Metastasis
h-prune affects anaplastic thyroid cancer invasion and metastasis.
Neoplasm Metastasis
h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
Neoplasm Metastasis
H-Prune through GSK-3? interaction sustains canonical WNT/?-catenin signaling enhancing cancer progression in NSCLC.
Neoplasm Metastasis
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Neoplasm Metastasis
Human metastasis regulator protein H-prune is a short-chain exopolyphosphatase.
Neoplasm Metastasis
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Neoplasm Metastasis
Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer.
Neoplasm Metastasis
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.
Neoplasm Metastasis
Overexpression of h-prune in breast cancer is correlated with advanced disease status.
Neoplasm Metastasis
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Neoplasm Metastasis
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis.
Neoplasm Metastasis
The phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomy.
Neoplasm Metastasis
Understanding h-prune biology in the fight against cancer.
Neoplasm Metastasis
Unraveling genes and pathways influenced by H-prune PDE overexpression: a model to study cellular motility.
Neoplasm Metastasis
Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study.
Neoplasms
3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Neoplasms
?-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.
Neoplasms
A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex.
Neoplasms
A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia.
Neoplasms
A lymphomagenic role for HIV beyond immune suppression?
Neoplasms
A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction.
Neoplasms
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
Neoplasms
Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.
Neoplasms
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
Neoplasms
Adrenocortical tumorigenesis: Lessons from genetics.
Neoplasms
Alterations of Phosphodiesterases in Adrenocortical Tumors.
Neoplasms
Anagrelide for Gastrointestinal Stromal Tumor.
Neoplasms
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.
Neoplasms
Calcium-dependent cyclic nucleotide phosphodiesterase from glial tumor cells.
Neoplasms
Calcium-dependent protein modulator of cyclic nucleotide phosphodiesterases from mouse epidermis.
Neoplasms
Calmodulin-dependent cyclic nucleotide phosphodiesterase in human cerebral cortex and glioblastoma multiforme.
Neoplasms
cAMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
Neoplasms
Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells.
Neoplasms
Clinicopathological correlates of adrenal Cushing's syndrome.
Neoplasms
Cloning and characterization of the cyclic guanosine monophosphate-inhibited phosphodiesterase PDE3A expressed in mouse oocyte.
Neoplasms
Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures.
Neoplasms
Cyclic nucleotide phosphodiesterase activity in muscle of patients with carcinoma.
Neoplasms
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Neoplasms
Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
Neoplasms
Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells.
Neoplasms
Decreased response to cAMP in the glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats.
Neoplasms
Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.
Neoplasms
Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.
Neoplasms
Differential phosphodiesterase expression and cytosolic Ca2+ in human CNS tumour cells and in non-malignant and malignant cells of rat origin.
Neoplasms
Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3.
Neoplasms
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Neoplasms
Distribution of cyclic 3',5'-phosphodiesterase, monoamine oxidase & beta-glucuronidase in liver tumours induced by technical grade hexachlorocyclohexane in inbred swiss mice.
Neoplasms
Domain mapping on the human metastasis regulator protein h-Prune reveals a C-terminal dimerization domain.
Neoplasms
Effects of a calcium-antagonist (flunarizine) on the in vitro growth of B16 mouse melanoma cells.
Neoplasms
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.
Neoplasms
Endothelial Actions of ANP Enhance Myocardial Inflammatory Infiltration in the Early Phase After Acute Infarction.
Neoplasms
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Neoplasms
Experimental intraocular malignancy: the effect of intracameral perfusion.
Neoplasms
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Neoplasms
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Neoplasms
Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays.
Neoplasms
Genome-wide transcriptional analysis of Aristolochia manshuriensis induced gastric carcinoma.
Neoplasms
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Neoplasms
gH625 is a viral derived peptide for effective delivery of intrinsically disordered proteins.
Neoplasms
Glycerophosphodiester phosphodiesterase 1 (GDE1) acts as a potential tumor suppressor and is a novel therapeutic target for non-mucin-producing colon adenocarcinoma.
Neoplasms
Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions.
Neoplasms
Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.
Neoplasms
h-prune affects anaplastic thyroid cancer invasion and metastasis.
Neoplasms
h-prune Is an Independent Prognostic Marker for Survival in Esophageal Squamous Cell Carcinoma.
Neoplasms
h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
Neoplasms
H-Prune through GSK-3? interaction sustains canonical WNT/?-catenin signaling enhancing cancer progression in NSCLC.
Neoplasms
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Neoplasms
Human metastasis regulator protein H-prune is a short-chain exopolyphosphatase.
Neoplasms
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.
Neoplasms
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Neoplasms
Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients.
Neoplasms
Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumors.
Neoplasms
Immunocytochemical demonstration of calmodulin and its activated forms in normal and carcinomatous human mammary tissue.
Neoplasms
Inactivation of NF-?B p65 (RelA) in Liver Improves Insulin Sensitivity and Inhibits cAMP/PKA Pathway.
Neoplasms
Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation.
Neoplasms
Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).
Neoplasms
Increased cyclic nucleotide phosphodiesterase activity associated with proliferation and cancer in human and murine lymphoid cells.
Neoplasms
Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer.
Neoplasms
Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.
Neoplasms
Inhibition of TPL2 by interferon-? suppresses bladder cancer through activation of PDE4D.
Neoplasms
Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma.
Neoplasms
Isolation and characterization of calmodulin from an insulin-secreting tumour.
Neoplasms
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Neoplasms
Low-Concentration Oxygen/Ozone Treatment Attenuated Radiculitis and Mechanical Allodynia via PDE2A-cAMP/cGMP-NF-?B/p65 Signaling in Chronic Radiculitis Rats.
Neoplasms
Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
Neoplasms
Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice.
Neoplasms
miR-139/PDE2A-Notch1 feedback circuit represses stemness of gliomas by inhibiting Wnt/?-catenin signaling.
Neoplasms
miR-5701 promoted apoptosis of clear cell renal cell carcinoma cells by targeting phosphodiesterase-1B.
Neoplasms
Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line.
Neoplasms
Molecular Genetic and Genomic Alterations in Cushing's Syndrome and Primary Aldosteronism.
Neoplasms
Multiple endocrine neoplasias: advances and challenges for the future.
Neoplasms
Multiple forms of cyclic nucleotide phosphodiesterase in a murine adrenal cortex cell line (Y-1).
Neoplasms
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Neoplasms
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction.
Neoplasms
New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).
Neoplasms
New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview.
Neoplasms
Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.
Neoplasms
Novel protein inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase from glioblastoma multiforme.
Neoplasms
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.
Neoplasms
Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.
Neoplasms
Overexpression of h-prune in breast cancer is correlated with advanced disease status.
Neoplasms
PDE10A antibodies in autoimmune encephalitis: A possible marker of cancer immunotherapy?
Neoplasms
PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma.
Neoplasms
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.
Neoplasms
PDE4 subtypes in cancer.
Neoplasms
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/?-catenin transcription, cancer cell growth, and tumor immunity.
Neoplasms
Phenotypic and genotypic features of a large kindred with a germline AIP variant.
Neoplasms
Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
Neoplasms
Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Neoplasms
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking ?-catenin and MAPK signaling.
Neoplasms
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and ?-catenin-dependent TCF transcriptional activity.
Neoplasms
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Neoplasms
Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors.
Neoplasms
Phosphodiesterase 11A (PDE11A) Genetic Variants May Increase Susceptibility to Prostatic Cancer.
Neoplasms
Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.
Neoplasms
Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland.
Neoplasms
Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells.
Neoplasms
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Neoplasms
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Neoplasms
Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma.
Neoplasms
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
Neoplasms
Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
Neoplasms
Phosphodiesterase sequence variants may predispose to prostate cancer.
Neoplasms
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Neoplasms
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Neoplasms
Platyphylloside Isolated From Betula platyphylla Inhibit Adipocyte Differentiation and Induce Lipolysis Via Regulating Adipokines Including PPAR? in 3T3-L1 Cells.
Neoplasms
PRKAR1A mutations in primary pigmented nodular adrenocortical disease.
Neoplasms
Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
Neoplasms
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis.
Neoplasms
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Neoplasms
RNA Sequencing revealed differentially expressed genes functionally associated with immunity and tumor suppression during latent phase infection of a vv?+?MDV in chickens.
Neoplasms
Robustadial A and B from Eucalyptus globulus Labill. and their anticancer activity as selective tyrosyl-DNA phosphodiesterase 2 inhibitors.
Neoplasms
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.
Neoplasms
Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide.
Neoplasms
Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
Neoplasms
Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
Neoplasms
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Neoplasms
Targeting tumor cells based on Phosphodiesterase 3A expression.
Neoplasms
The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.
Neoplasms
The insulin-like effects of phorbol myristate acetate (PMA) in the isolated fat cell.
Neoplasms
The involvement of the 3':5'-cyclic-AMP phosphodiesterase in transformation and growth of crown-gall tumors in Bryophyllum daigremontianum.
Neoplasms
The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
Neoplasms
Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors.
Neoplasms
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
Neoplasms
Understanding h-prune biology in the fight against cancer.
Neoplasms
Unraveling genes and pathways influenced by H-prune PDE overexpression: a model to study cellular motility.
Neoplasms
Unraveling the molecular basis of micronodular adrenal hyperplasia.
Neoplasms
Whole genome sequencing analysis identifies recurrent structural alterations in esophageal squamous cell carcinoma.
Neoplasms
Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity.
Neoplasms
[Biochemical differences in the tumor cells of 5-fluorouracil-sensitive and -resistant strains of Ehrlich ascitic carcinoma]
Neoplasms
[Concentration and metabolism of cyclic AMP during the early stages of hepatoma 22a growth]
Neoplasms
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Neoplasms
[Participation of the adenyl cyclase system in estradiol-activated growth of tumors in rat mammary glands]
Neoplasms, Germ Cell and Embryonal
Alterations of Phosphodiesterases in Adrenocortical Tumors.
Neoplasms, Germ Cell and Embryonal
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Nephrolithiasis
PDE1A polymorphism contributes to the susceptibility of nephrolithiasis.
Nervous System Diseases
AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.
Nervous System Diseases
Development of a cell-based assay for screening of phosphodiesterase 10A (PDE10A) inhibitors using a stable recombinant HEK-293 cell line expressing high levels of PDE10A.
Nervous System Diseases
Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.
Nervous System Diseases
Identification and Localization of the Cyclic Nucleotide Phosphodiesterase 10A in Bovine Testis and Mature Spermatozoa.
Nervous System Diseases
Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Nervous System Diseases
Potential of PDE10A Inhibitors as Treatment for Schizophrenia and Other Neurological Disorders.
Nervous System Diseases
Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
Neurobehavioral Manifestations
A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia.
Neurobehavioral Manifestations
Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
Neurobehavioral Manifestations
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Neurobehavioral Manifestations
Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study.
Neurobehavioral Manifestations
Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington's Disease.
Neurobehavioral Manifestations
The role of phosphodiesterases in schizophrenia : therapeutic implications.
Neuroblastoma
A further study on the regulation of cyclic nucleotide phosphodiesterase activity in neuroblastoma cells: effect of growth.
Neuroblastoma
Caffeine elicited withdrawal signs in morphine-dependent rhesus monkeys.
Neuroblastoma
Characterization of 3':5' cyclic nucleotide phosphodiesterase activities of mouse neuroblastoma N18TG2 cells.
Neuroblastoma
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Cyclic nucleotide phosphodiesterase isozymes in neuroblastoma cells.
Neuroblastoma
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Neuroblastoma
Differences and similarities between guanosine 3',5'-cyclic monophosphate phosphodiesterase and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in neuroblastoma cells in culture.
Neuroblastoma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Neuroblastoma
Effect of hyperthermia in combination with vitamin E and cyclic AMP on neuroblastoma cells in culture.
Neuroblastoma
Identification and molecular characterization of a novel PDE4D11 cAMP-specific phosphodiesterase isoform.
Neuroblastoma
In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors.
Neuroblastoma
Increased expression of ubiquitin during adenosine 3',5'-cyclic monophosphate-induced differentiation of neuroblastoma cells in culture.
Neuroblastoma
Multiple neurite formation in neuroblastoma cell lines by griseolic acid, a potent inhibitor of cyclic nucleotide phosphodiesterases.
Neuroblastoma
Neurite formation in NG108-15 neuroblastoma x glioma hybrid cells by KS-505a, a potent inhibitor of brain cyclic nucleotide phosphodiesterase.
Neuroblastoma
Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid.
Neuroblastoma
PS-990, a novel neuritogenic compound from Acremonium sp.
Neuroblastoma
Regression and differentiation of neuroblastoma tumors in mice treated with differentiating agents--prostaglandin E1 and a phosphodiesterase inhibitor, RO 20-1724.
Neuroblastoma
Role of phosphodiesterase II in cross talk between cGMP and cAMP in human neuroblastoma NB-OK-1 cells.
Neurodegenerative Diseases
Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
Neurodegenerative Diseases
Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [(11) C]T-773 in nonhuman primates.
Neurodegenerative Diseases
Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Neurodegenerative Diseases
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1.
Neurodegenerative Diseases
Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques.
Neurodegenerative Diseases
Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.
Neurodegenerative Diseases
Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
Neurodegenerative Diseases
Neurodegenerative disease: Changes in brain phosphodiesterase 10A levels in neurodegenerative basal ganglia disorders.
Neurodegenerative Diseases
Papaverine, a Phosphodiesterase 10A Inhibitor, Ameliorates Quinolinic Acid-Induced Synaptotoxicity in Human Cortical Neurons.
Neurodegenerative Diseases
Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Neurodegenerative Diseases
Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
Neurodegenerative Diseases
Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.
Neurodegenerative Diseases
Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?
Neurodegenerative Diseases
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Neurodegenerative Diseases
Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities.
Neurodegenerative Diseases
The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
Neuroinflammatory Diseases
Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages.
Neuroinflammatory Diseases
Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations.
Neuroinflammatory Diseases
Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.
Neuroinflammatory Diseases
The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
Neuroinflammatory Diseases
The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson's Disease Mouse Models.
Neuromuscular Diseases
The metabolism of cyclic-3'-5'-adenosine monophosphate (cAMP) in diseased muscle.
Non-alcoholic Fatty Liver Disease
Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis.
Non-alcoholic Fatty Liver Disease
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Non-alcoholic Fatty Liver Disease
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Obesity
A novel thermoregulatory role for PDE10A in mouse and human adipocytes.
Obesity
Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity.
Obesity
Analyses of shared genetic factors between asthma and obesity in children.
Obesity
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Obesity
Genetic Deletion and Pharmacological Inhibition of PDE10A Protects Mice from Diet-Induced Obesity and Insulin Resistance.
Obesity
Hyperinsulinemia promotes heterologous desensitization of ?2 adrenergic receptor in airway smooth muscle in obesity.
Obesity
Increased Adipocyte S-Nitrosylation Targets Anti-lipolytic Action of Insulin: RELEVANCE TO ADIPOSE TISSUE DYSFUNCTION IN OBESITY.
Obesity
Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKK{varepsilon} and TBK1.
Obesity
New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview.
Obesity
Platyphylloside Isolated From Betula platyphylla Inhibit Adipocyte Differentiation and Induce Lipolysis Via Regulating Adipokines Including PPAR? in 3T3-L1 Cells.
Obesity
PRDM16 Gene Polymorphism Is Associated with Obesity and Blood Lipids Profiles in Saudi Population.
Obesity
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes in northern Chinese.
Obesity
The K121Q polymorphism of ENPP1 and peripheral arterial disease.
Obesity
White to beige conversion in PDE3B KO adipose tissue through activation of AMPK signaling and mitochondrial function.
Obesity, Abdominal
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Obesity, Morbid
GNAS, PDE4D, and PRKAR1A Mutations and GNAS Methylation Changes Are Not a Common Cause of Isolated Early-Onset Severe Obesity Among Finnish Children.
Obstetric Labor, Premature
Uterus-relaxing effect of ?(2) -agonists in combination with phosphodiesterase inhibitors: Studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
Oligodendroglioma
Molecular markers that identify human astrocytomas and oligodendrogliomas.
Optic Nerve Injuries
Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats.
Optic Neuropathy, Ischemic
Progressive damage along the optic nerve following induction of crush injury or rodent anterior ischemic optic neuropathy in transgenic mice.
Osteoarthritis
Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice.
Osteoarthritis
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Osteoarthritis
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Osteomalacia
Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice.
Pancreatic Neoplasms
Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions.
Pancreatic Neoplasms
h-prune affects anaplastic thyroid cancer invasion and metastasis.
Pancreatic Neoplasms
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Pancreatic Neoplasms
Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer.
Paraganglioma
Multiple endocrine neoplasias: advances and challenges for the future.
Paralysis
Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
Parkinson Disease
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
Parkinson Disease
A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
Parkinson Disease
Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme.
Parkinson Disease
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
Parkinson Disease
Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
Parkinson Disease
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
Parkinson Disease
Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.
Parkinson Disease
Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
Parkinson Disease
Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Parkinson Disease
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Parkinson Disease
Emerging biology of PDE10A.
Parkinson Disease
Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging.
Parkinson Disease
Identification of novel cyclic nucleotide phosphodiesterase gene cDNAs in the brain of guinea pig.
Parkinson Disease
Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl.
Parkinson Disease
Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
Parkinson Disease
Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice.
Parkinson Disease
Molecular Imaging of PDE10A Knockout Mice with a Novel PET Radiotracer: [(11)C]T-773.
Parkinson Disease
N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
Parkinson Disease
PDE8B mutation is not associated with Parkinson's disease in a Taiwanese population.
Parkinson Disease
Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.
Parkinson Disease
Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?
Parkinson Disease
Phosphodiesterases in neurodegenerative disorders.
Parkinson Disease
The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
Parkinson Disease
The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson's Disease Mouse Models.
Parkinson Disease
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
Parkinson Disease
Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats.
Parkinson Disease
[Analysis of SMPD1 gene mutations in Chinese patients with Parkinson's disease].
Parkinsonian Disorders
Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.
Parkinsonian Disorders
PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Parkinsonian Disorders
The Emerging Role of Phosphodiesterases in Movement Disorders.
Pediatric Obesity
GNAS, PDE4D, and PRKAR1A Mutations and GNAS Methylation Changes Are Not a Common Cause of Isolated Early-Onset Severe Obesity Among Finnish Children.
Peripheral Arterial Disease
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Peripheral Arterial Disease
Cilostazol Stimulates Revascularisation in Response to Ischaemia via an eNOS-Dependent Mechanism.
Peripheral Arterial Disease
Effect of cilostazol on arteriovenous fistula in hemodialysis patients.
Peripheral Arterial Disease
K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.
Peripheral Arterial Disease
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol.
Peripheral Vascular Diseases
Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence.
Pheochromocytoma
Multiple endocrine neoplasias: advances and challenges for the future.
Pheochromocytoma
Phosphodiesterase 2 negatively regulates adenosine-induced transcription of the tyrosine hydroxylase gene in PC12 rat pheochromocytoma cells.
Pheochromocytoma
Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
Photophobia
Engineering of a red-light-activated human cAMP/cGMP-specific phosphodiesterase.
Picornaviridae Infections
Effects of TDP2/VPg Unlinkase Activity on Picornavirus Infections Downstream of Virus Translation.
Pituitary Neoplasms
Phosphodiesterases and cAMP Pathway in Pituitary Diseases.
Pneumonia
Phosphodiesterase 10A Is a Key Mediator of Lung Inflammation.
Pneumonia, Pneumococcal
Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia.
Polycystic Kidney Diseases
Generation and phenotypic characterization of Pde1a mutant mice.
Polycystic Kidney Diseases
Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies.
Polycystic Kidney, Autosomal Dominant
Generation and phenotypic characterization of Pde1a mutant mice.
Polycystic Ovary Syndrome
PDE8A genetic variation, polycystic ovary syndrome and androgen levels in women.
Polyuria
AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Pre-Eclampsia
A Family Based Study of Carbon Monoxide and Nitric Oxide Signalling Genes and Preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
S-100 antigen and calmodulin in human leukemic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Phosphatidylethanolamine methylase and cyclic nucleotide phosphodiesterase activities in human B lymphoid hemopathies]
Primary Dysautonomias
Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.
Progeria
Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals.
Prostatic Hyperplasia
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Prostatic Hyperplasia
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
Prostatic Neoplasms
A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction.
Prostatic Neoplasms
Alterations of Phosphodiesterases in Adrenocortical Tumors.
Prostatic Neoplasms
Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance.
Prostatic Neoplasms
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Prostatic Neoplasms
Identification of PDE4D as a Proliferation Promoting Factor in Prostate Cancer Using a Sleeping Beauty Transposon-Based Somatic Mutagenesis Screen.
Prostatic Neoplasms
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
Prostatic Neoplasms
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
Pseudohypoparathyroidism
Fourteen-year follow-up of a child with acroscyphodysplasia with emphasis on the need for multidisciplinary management: a case report.
Pseudohypoparathyroidism
Identification of novel mutations confirms Pde4d as a major gene causing acrodysostosis.
Pseudohypoparathyroidism
Screening of PRKAR1A and PDE4D in a Large Italian Series of Patients Clinically Diagnosed with Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism.
Pseudopseudohypoparathyroidism
Identification of novel mutations confirms Pde4d as a major gene causing acrodysostosis.
Psoriasis
Apremilast: first global approval.
Psoriasis
Dyphylline liposomes for delivery to the skin.
Psoriasis
Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Psychomotor Agitation
Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
Pulmonary Arterial Hypertension
Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells.
Pulmonary Arterial Hypertension
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
Pulmonary Disease, Chronic Obstructive
3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.
Pulmonary Disease, Chronic Obstructive
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
Pulmonary Disease, Chronic Obstructive
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Pulmonary Disease, Chronic Obstructive
Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism.
Pulmonary Disease, Chronic Obstructive
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Pulmonary Disease, Chronic Obstructive
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Pulmonary Disease, Chronic Obstructive
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.
Pulmonary Disease, Chronic Obstructive
Epigenome-wide association study on asthma and chronic obstructive pulmonary disease overlap reveals aberrant DNA methylations related to clinical phenotypes.
Pulmonary Disease, Chronic Obstructive
Polymorphisms in PDE4D are Associated with a Risk of COPD in Non-Emphysematous Koreans.
Pulmonary Disease, Chronic Obstructive
Retinoic acid receptor alpha: One of plasma biomarkers associated with exacerbation of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast and aquaporin-2 regulation in rat renal inner medullary collecting duct.
Pulmonary Disease, Chronic Obstructive
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Pulmonary Disease, Chronic Obstructive
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
Pulmonary Disease, Chronic Obstructive
The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD.
Radiculopathy
Low-Concentration Oxygen/Ozone Treatment Attenuated Radiculitis and Mechanical Allodynia via PDE2A-cAMP/cGMP-NF-?B/p65 Signaling in Chronic Radiculitis Rats.
Radiculopathy
Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.
Rectal Neoplasms
Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
Refractive Errors
Genome-Wide Association of Genetic Variants With Refraction, Axial Length, and Corneal Curvature: A Longitudinal Study of Chinese Schoolchildren.
Renal Insufficiency
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Reperfusion Injury
Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-?1 signaling.
Reperfusion Injury
Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury.
Reperfusion Injury
Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury.
Reperfusion Injury
Dynamic changes of post-ischemic hepatic microcirculation improved by a pre-treatment of phosphodiesterase-3 inhibitor, milrinone.
Reperfusion Injury
Implication of Protein Kinase A for a Hepato-Protective Mechanism of Milrinone Pretreatment.
Reperfusion Injury
Pretreatment with a Phosphodiesterase-3 Inhibitor, Milrinone, Reduces Hepatic Ischemia-Reperfusion Injury, Minimizing Pericentral Zone-Based Liver and Small Intestinal Injury in Rats.
Reperfusion Injury
Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
Respiratory Distress Syndrome
Effects of PDE3 Inhibitor Olprinone on the Respiratory Parameters, Inflammation, and Apoptosis in an Experimental Model of Acute Respiratory Distress Syndrome.
Respiratory Insufficiency
The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report.
Retinal Degeneration
Cyclic nucleotide phosphodiesterase activity in normal mice and mice with retinal degeneration.
Retinal Degeneration
[Biochemical disorders in hereditary retinal degeneration: changes in cyclic nucleotide phosphodiesterase activity and rhodopsin concentration in the retinas of Campbell rats]
Retinal Degeneration
[Changes in the properties of photostimulated cyclic nucleotide phosphodiesterase from the retina of rats with hereditary retinal degeneration]
Retinal Dystrophies
[Protein inhibitor of cyclic nucleotide phosphodiesterase in the retina in hereditary degeneration]
Retinoblastoma
Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
Retinoblastoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Rett Syndrome
A Homozygous Splicing Mutation in PDE2A in a Family with Atypical Rett Syndrome.
Reye Syndrome
Cyclic nucleotide phosphodiesterase activities of the human liver: comparison between control and Reye's syndrome samples.
Sarcoidosis
Impaired G-proteins and cyclic nucleotide phosphodiesterase activity in T-lymphocytes from patients with sarcoidosis.
Sarcoma 37
[Interaction of sarcolysine with beta-adrenoreceptors in tumor cells]
Sarcoma, Avian
Calcium-dependent regulatory protein of cyclic nucleotide metabolism in normal and transformed chicken embryo fibroblasts.
Sarcoma, Kaposi
Increased prostaglandin E2 and cAMP phosphodiesterase levels in Kaposi's sarcoma--a virus against host defense mechanism.
Schistosomiasis
Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis.
Seizures
Chemical kindling induced by cAMP and transfer to electrical kindling.
Seizures
The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities.
Seizures
Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment.
Sepsis
Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Sepsis
Effects of selective phosphodiesterase 3 inhibition in the perfused liver of the rat after endotoxin treatment.
Shock, Septic
Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Skin Diseases
Pentoxifylline and skin inflammation.
Sleep Deprivation
Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory.
Spasm
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.
Spasm
Inhibition of human cAMP-phosphodiesterase as a mechanism of the spasmolytic effect of Matricaria recutita L.
Spasm
The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery.
Spinocerebellar Ataxias
Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23).
Spinocerebellar Ataxias
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1.
Spinocerebellar Ataxias
TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks.
Spondylitis, Ankylosing
Apremilast: first global approval.
Starvation
HIV p17 enhances T cell proliferation by suppressing autophagy through the p17-OLA1-GSK3? axis under nutrient starvation.
Starvation
Induction of an extracellular cyclic nucleotide phosphodiesterase as an accessory ribonucleolytic activity during phosphate starvation of cultured tomato cells.
Starvation
Yeast pseudohyphal growth is regulated by GPA2, a G protein alpha homolog.
Status Asthmaticus
Enoximone in status asthmaticus.
Stomach Neoplasms
gH625 is a viral derived peptide for effective delivery of intrinsically disordered proteins.
Stomach Neoplasms
Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer.
Stomach Neoplasms
MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D.
Stomach Neoplasms
Understanding h-prune biology in the fight against cancer.
Stroke
Advances in the genetic basis of coronary artery disease.
Stroke
Advancing stroke therapeutics through genetic understanding.
Stroke
ALOX5AP gene and the PDE4D gene in a central European population of stroke patients.
Stroke
Association between PDE4D gene and ischemic stroke: recent advancements.
Stroke
Association between phosphodiesterase 4D gene and ischaemic stroke.
Stroke
Association between the PDE4D gene and ischemic stroke in Han Chinese population.
Stroke
Association of GWAS-susceptibility loci with ischemic stroke recurrence in a Han Chinese population.
Stroke
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Stroke
Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population.
Stroke
Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population.
Stroke
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Stroke
Association of SNP41, SNP56 and a novel SNP in PDE4D gene with stroke and its subtypes.
Stroke
Cardiovascular effects of levosimendan during rewarming from hypothermia in rat.
Stroke
Correction to: Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type.
Stroke
Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients.
Stroke
Effects of PDE4 pathway inhibition in rat experimental stroke.
Stroke
Erythropoietin amplifies stroke-induced oligodendrogenesis in the rat.
Stroke
Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.
Stroke
Genetics of ischemic stroke: Indian perspective.
Stroke
Identification of pleiotropic genes between risk factors of stroke by multivariate metaCCA analysis.
Stroke
Inflammatory system gene polymorphism and the risk of stroke: a case-control study in an Indian population.
Stroke
Influence of Genetic Variation in PDE3A on Endothelial Function and Stroke.
Stroke
Linkage of ischemic stroke to the PDE4D region on 5q in a Swedish population.
Stroke
Many hypotheses but no replication for the association between PDE4D and stroke.
Stroke
Molecular genetics of coronary artery disease.
Stroke
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.
Stroke
PDE4D and stroke: a real advance or a case of the Emperor's new clothes?
Stroke
PDE4D gene in the STRK1 region on 5q12: susceptibility gene for ischemic stroke.
Stroke
Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type.
Stroke
Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population.
Stroke
Phosphodiesterase 4D gene polymorphism is associated with ischaemic and haemorrhagic stroke.
Stroke
Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke.
Stroke
Phosphodiesterase4D (PDE4D)--A risk factor for atrial fibrillation and stroke?
Stroke
Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation.
Stroke
Research actuality in the genetics of stroke.
Stroke
Role of FLAP and PDE4D in Myocardial Infarction and Stroke: Target Discovery and Future Treatment Options.
Stroke
Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
Stroke
Stroke genetics--focus on PDE4D gene.
Stroke
Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
Stroke
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Stroke
The phosphodiesterase puzzlebox: PDE4D and stroke.
Stroke
Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?
Stroke
[Analysis of the polymorphic variants of the PDE4D gene in patients with acute stroke in the Moldavian population].
Stroke
[Association between mRNA level of Pde4d and Alox5ap and hypertensive stroke as well as hypertension in rats.]
Stroke
[Association of cerebral stroke with a phosphodiesterase 4D (PDE4D) gene polymorphism in the Moscow population].
Stroke
[Association study between PDE4D gene polymorphism and ischemic stroke].
Stroke
[Phosphodiesterase 4D (PDE4D) gene polymorphism in patients with acute stroke from Moscow]
Subarachnoid Hemorrhage
Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial.
Subarachnoid Hemorrhage
Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Supranuclear Palsy, Progressive
Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
Synucleinopathies
Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.
Tachycardia
[Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting].
Tardive Dyskinesia
Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats.
Tauopathies
Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline.
Testicular Neoplasms
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Testicular Neoplasms
PDE11A gene polymorphism in testicular cancer: sperm parameters and hormonal profile.
Testicular Neoplasms
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Thromboinflammation
Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions.
Thrombosis
Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
Thrombosis
Antithrombotic effects of BMY21190, an inhibitor of cAMP phosphodiesterase, in a canine model of coronary artery thrombosis.
Thrombosis
Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
Thrombosis
Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives.
Thrombosis
K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.
Thrombosis
Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility.
Thrombosis
Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.
Thrombosis
Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation.
Thyroid Carcinoma, Anaplastic
h-prune affects anaplastic thyroid cancer invasion and metastasis.
Thyroid Diseases
Association of established hypothyroidism-associated genetic variants with Hashimoto's thyroiditis.
Thyroid Diseases
Subclinical thyroid disease and single nucleotide polymorphisms in reproductive-age women in areas of Shanxi Province, China, where iodine exposure is excessive.
Thyroid Neoplasms
h-prune affects anaplastic thyroid cancer invasion and metastasis.
Thyroid Neoplasms
Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.
Tinnitus
Effect of a 4-Week Treatment with Cilostazol in Patients with Chronic Tinnitus: A Randomized, Prospective, Placebo-controlled, Double-blind, Pilot Study.
Trypanosomiasis, African
Discovery of Novel Trypanosoma brucei Phosphodiesterase B1 Inhibitors by Virtual Screening against the Unliganded TbrPDEB1 Crystal Structure.
Trypanosomiasis, African
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Tuberculosis
A mycobacterial cyclic AMP phosphodiesterase that moonlights as a modifier of cell wall permeability.
Tuberculosis
Characterization of an evolutionarily conserved metallophosphoesterase that is expressed in the fetal brain and associated with the WAGR syndrome.
Tuberculosis
Structural and biochemical analysis of the Rv0805 cyclic nucleotide phosphodiesterase from Mycobacterium tuberculosis.
Tuberculosis
The Rv0805 gene from Mycobacterium tuberculosis encodes a 3',5'-cyclic nucleotide phosphodiesterase: biochemical and mutational analysis.
Tuberculosis, Bovine
ERAP1 and PDE8A Are Downregulated in Cattle Protected against Bovine Tuberculosis.
Urinary Bladder Neck Obstruction
Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
Urinary Bladder Neck Obstruction
Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor.
Urinary Bladder Neoplasms
Inhibition of TPL2 by interferon-? suppresses bladder cancer through activation of PDE4D.
Vascular System Injuries
Role of cAMP-Phosphodiesterase 1C Signaling in Regulating Growth Factor Receptor Stability, Vascular Smooth Muscle Cell Growth, Migration, and Neointimal Hyperplasia.
Vasospasm, Intracranial
Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Vasospasm, Intracranial
Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial.
Vasospasm, Intracranial
Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial.
Vasospasm, Intracranial
Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Ventilator-Induced Lung Injury
Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.
Ventricular Fibrillation
Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.
Vesicular Stomatitis
Inhibitory effect of papaverine on RNA and protein synthesis of vesicular stomatitis virus.
Virus Diseases
Inhibition of topoisomerase IIA (Top2?) induces telomeric DNA damage and T cell dysfunction during chronic viral infection.
Virus Diseases
Inhibitory effect of papaverine on RNA and protein synthesis of vesicular stomatitis virus.
Virus Diseases
Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.
WAGR Syndrome
Characterization of an evolutionarily conserved metallophosphoesterase that is expressed in the fetal brain and associated with the WAGR syndrome.
Whooping Cough
Activation of Bordetella pertussis adenylate cyclase by the carboxyl-terminal tryptic fragment of calmodulin.
Whooping Cough
Effect of N6-(L-2-phenylisopropyl)adenosine and insulin on cAMP metabolism in 3T3-L1 adipocytes.
Whooping Cough
Inhibition by glucagon of the cGMP-inhibited low-Km cAMP phosphodiesterase in heart is mediated by a pertussis toxin-sensitive G-protein.
Whooping Cough
Inhibition by pertussis toxin of guanyl nucleotides exchange on transducin in bovine rod cell membranes.
Whooping Cough
Meiotic resumption in response to luteinizing hormone is independent of a Gi family G protein or calcium in the mouse oocyte.
Whooping Cough
Protein kinase C activation and positive and negative agonist regulation of 3',5'-cyclic adenosine monophosphate levels in cultured rat Sertoli cells.
Whooping Cough
Selective regulation by pertussis toxin of insulin-induced activation of particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes.
Whooping Cough
Synthetic peptides based on the calmodulin-binding domain of myosin light chain kinase inhibit activation of other calmodulin-dependent enzymes.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.1.4.17 3',5'-cyclic-nucleotide phosphodiesterase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
